Vlado Perkovic , Jonathan C. Craig , Worawon Chailimpamontree , Caroline S. Fox , Guillermo Garcia-Garcia , Mohammed Benghanem Gharbi , Meg J. Jardine , Ikechi G. Okpechi , Neesh Pannu , Benedicte Stengel , Katherine R. Tuttle , Katrin Uhlig , Andrew S. Levey
{"title":"Action plan for optimizing the design of clinical trials in chronic kidney disease","authors":"Vlado Perkovic , Jonathan C. Craig , Worawon Chailimpamontree , Caroline S. Fox , Guillermo Garcia-Garcia , Mohammed Benghanem Gharbi , Meg J. Jardine , Ikechi G. Okpechi , Neesh Pannu , Benedicte Stengel , Katherine R. Tuttle , Katrin Uhlig , Andrew S. Levey","doi":"10.1016/j.kisu.2017.07.009","DOIUrl":null,"url":null,"abstract":"<div><p>High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"7 2","pages":"Pages 138-144"},"PeriodicalIF":89.6000,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.07.009","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney International Supplements","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2157171617300357","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 18
Abstract
High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.
期刊介绍：
Kidney International Supplements is published on behalf of the International Society of Nephrology (ISN) and comes complimentary as part of a subscription to Kidney International. Kidney International Supplements is a peer-reviewed journal whose focus is sponsored, topical content of interest to the nephrology community.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
